AB 710: Cannabidiol.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-07-09
Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 designated schedules, with the most restrictive limitations generally placed on controlled substances classified in Schedule I, and the least restrictive limitations generally placed on controlled substances classified in Schedule V. Existing law designates cannabis in Schedule I. Cannabidiol is a compound contained in cannabis.
Existing law restricts the prescription, furnishing, possession, sale, and use of controlled substances, including cannabis and synthetic cannabinoid compounds, and makes a violation of those laws a crime, except as specified.
This bill, if one of specified changes in federal law regarding the controlled substance cannabidiol occurs, would deem a physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses a product composed of cannabidiol, in accordance with federal law, to be in compliance with state law governing those acts. The bill would also provide that upon the effective date of one of those changes in federal law regarding cannabidiol, the prescription, furnishing, dispensing, transfer, transportation, possession, or use of that product in accordance with federal law is for a legitimate medical purpose and is authorized pursuant to state law.
Existing law, the Medicinal and Adult-Use Cannabis Regulation and Safety Act, regulates the cultivation, processing, and sale of medicinal and adult-use cannabis within the state.
This bill would expressly exclude from regulation under that act, any medicinal product composed of cannabidiol approved by the federal Food and Drug Administration and either placed on a schedule of the federal Controlled Substances Act other than Schedule I, or exempted from one or more provisions of that act.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 designated schedules, with the most restrictive limitations generally placed on controlled substances classified in Schedule I, and the least restrictive limitations generally placed on controlled substances classified in Schedule V. Existing law designates cannabis in Schedule I. Cannabidiol is a compound contained in cannabis.
Existing law restricts the prescription, furnishing, possession, sale, and use of controlled substances, including cannabis and synthetic cannabinoid compounds, and makes a violation of those laws a crime, except as specified.
This bill, if one of specified changes in federal law regarding the controlled substance cannabidiol occurs, would deem a physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses a product composed of cannabidiol, in accordance with federal law, to be in compliance with state law governing those acts. The bill would also provide that upon the effective date of one of those changes in federal law regarding cannabidiol, the prescription, furnishing, dispensing, transfer, transportation, possession, or use of that product in accordance with federal law is for a legitimate medical purpose and is authorized pursuant to state law.
Existing law, the Medicinal and Adult-Use Cannabis Regulation and Safety Act, regulates the cultivation, processing, and sale of medicinal and adult-use cannabis within the state.
This bill would expressly exclude from regulation under that act, any medicinal product composed of cannabidiol approved by the federal Food and Drug Administration and either placed on a schedule of the federal Controlled Substances Act other than Schedule I, or exempted from one or more provisions of that act.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 designated schedules, with the most restrictive limitations generally placed on controlled substances classified in Schedule I, and the least restrictive limitations generally placed on controlled substances classified in Schedule V. Existing law designates cannabis in Schedule I. Cannabidiol is a compound contained in cannabis.
Existing law restricts the prescription, furnishing, possession, sale, and use of controlled substances, including cannabis and synthetic cannabinoid compounds, and makes a violation of those laws a crime, except as specified.
This bill, if one of specified changes in federal law regarding the controlled substance cannabidiol occurs, would deem a physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses a product composed of cannabidiol, in accordance with federal law, to be in compliance with state law governing those acts. The bill would also provide that upon the effective date of one of those changes in federal law regarding cannabidiol, the prescription, furnishing, dispensing, transfer, transportation, possession, or use of that product in accordance with federal law is for a legitimate medical purpose and is authorized pursuant to state law.
Existing law, the Medicinal and Adult-Use Cannabis Regulation and Safety Act, regulates the cultivation, processing, and sale of medicinal and adult-use cannabis within the state.
This bill would expressly exclude from regulation under that act, any medicinal product composed of cannabidiol approved by the federal Food and Drug Administration and either placed on a schedule of the federal Controlled Substances Act other than Schedule I, or exempted from one or more provisions of that act.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 designated schedules, with the most restrictive limitations generally placed on controlled substances classified in Schedule I, and the least restrictive limitations generally placed on controlled substances classified in Schedule V. Existing law designates cannabis in Schedule I. Cannabidiol is a compound contained in cannabis.
Existing law restricts the prescription, furnishing, possession, sale, and use of controlled substances, including cannabis and synthetic cannabinoid compounds, and makes a violation of those laws a crime, except as specified.
This bill, if one of specified changes in federal law regarding the controlled substance cannabidiol occurs, would deem a physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses a product composed of cannabidiol, in accordance with federal law, to be in compliance with state law governing those acts. The bill would also provide that upon the effective date of one of those changes in federal law regarding cannabidiol, the prescription, furnishing, dispensing, transfer, transportation, possession, or use of that product in accordance with federal law is for a legitimate medical purpose and is authorized pursuant to state law.
Existing law, the Medicinal and Adult-Use Cannabis Regulation and Safety Act, regulates the cultivation, processing, and sale of medicinal and adult-use cannabis within the state.
This bill would expressly exclude from regulation under that act, any medicinal product composed of cannabidiol approved by the federal Food and Drug Administration and either placed on a schedule of the federal Controlled Substances Act other than Schedule I, or exempted from one or more provisions of that act.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law generally requires these boards to meet at least 3 times each calendar year, and at least once in northern California and once in southern California per calendar year.This bill would require a board to meet once every other calendar year in rural California.Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law generally requires these boards to meet at least 3 times each calendar year, and at least once in northern California and once in southern California per calendar year.
This bill would require a board to meet once every other calendar year in rural northern California.
Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law generally requires these boards to meet at least 3 times each calendar year, and at least once in northern California and once in southern California per calendar year.
This bill would require a board to meet once every other calendar year in rural northern California.
Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law provides that these boards are established to ensure that private businesses and professions are regulated to protect the people of this state.This bill would make a nonsubstantive change to this provision.Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law provides that these boards are established to ensure that private businesses and professions are regulated to protect the people of this state.
This bill would make a nonsubstantive change to this provision.
The Legislature finds and declares that both children and adults with epilepsy are in desperate need of new treatment options and that cannabidiol has shown potential as an effective treatment option. If federal laws prohibiting the prescription of medications composed of cannabidiol are repealed or if an exception from the general prohibition is enacted permitting the prescription of drugs composed of cannabidiol, patients should have rapid access to this treatment option. The availability of this new prescription medication is intended to augment, not to restrict or otherwise amend, other cannabinoid treatment modalities including, but not limited to, industrial hemp products and derivatives containing cannabidiol, currently available under state law.
SEC. 2.Section 26002 is added to the Business and Professions Code, to read:26002.This division shall not apply to any product containing cannabidiol that has been approved by the federal Food and Drug Administration that has either been placed on a schedule of the federal Controlled Substances Act other than Schedule I or has been exempted from one or more provisions of that act, and that is intended for prescribed use for the treatment of a medical condition.
SEC. 3.Section 11150.2 is added to the Health and Safety Code, to read:11150.2.(a)Notwithstanding any other law, if cannabidiol is excluded from Schedule I of the federal Controlled Substances Act and placed on a schedule of the act other than Schedule I, or if a product composed of cannabidiol is approved by the federal Food and Drug Administration and either placed on a schedule of the act other than Schedule I, or exempted from one or more provisions of the act, so as to permit a physician, pharmacist, or other authorized healing arts licensee acting within his or her scope of practice, to prescribe, furnish, or dispense that product, the physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses that product in accordance with federal law shall be deemed to be in compliance with state law governing those acts.
(b)For purposes of this chapter, upon the effective date of one of the changes in federal law described in subdivision (a), notwithstanding any other state law, a product composed of cannabidiol may be prescribed, furnished, dispensed, transferred, transported, possessed, or used in accordance with federal law and is authorized pursuant to state law.
(c)This section does not apply to any product containing cannabidiol that is made or derived from industrial hemp, as defined in Section 11018.5 and regulated pursuant to that section.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available, it is necessary that this act take effect immediately.
The Legislature finds and declares that both children and adults with epilepsy are in desperate need of new treatment options and that cannabidiol has shown potential as an effective treatment option. If federal laws prohibiting the prescription of medications composed of cannabidiol are repealed or if an exception from the general prohibition is enacted permitting the prescription of drugs composed of cannabidiol, patients should have rapid access to this treatment option. The availability of this new prescription medication is intended to augment, not to restrict or otherwise amend, other cannabinoid treatment modalities including, but not limited to, industrial hemp products and derivatives containing cannabidiol, currently available under state law.
SEC. 2.Section 26002 is added to the Business and Professions Code, to read:26002.This division shall not apply to any product containing cannabidiol that has been approved by the federal Food and Drug Administration that has either been placed on a schedule of the federal Controlled Substances Act other than Schedule I or has been exempted from one or more provisions of that act, and that is intended for prescribed use for the treatment of a medical condition.
SEC. 3.Section 11150.2 is added to the Health and Safety Code, to read:11150.2.(a)Notwithstanding any other law, if cannabidiol is excluded from Schedule I of the federal Controlled Substances Act and placed on a schedule of the act other than Schedule I, or if a product composed of cannabidiol is approved by the federal Food and Drug Administration and either placed on a schedule of the act other than Schedule I, or exempted from one or more provisions of the act, so as to permit a physician, pharmacist, or other authorized healing arts licensee acting within his or her scope of practice, to prescribe, furnish, or dispense that product, the physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses that product in accordance with federal law shall be deemed to be in compliance with state law governing those acts.
(b)For purposes of this chapter, upon the effective date of one of the changes in federal law described in subdivision (a), notwithstanding any other state law, a product composed of cannabidiol may be prescribed, furnished, dispensed, transferred, transported, possessed, or used in accordance with federal law and is authorized pursuant to state law.
(c)This section does not apply to any product containing cannabidiol that is made or derived from industrial hemp, as defined in Section 11018.5 and regulated pursuant to that section.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available, it is necessary that this act take effect immediately.
The Legislature finds and declares that both children and adults with epilepsy are in desperate need of new treatment options and that cannabidiol has shown potential as an effective treatments treatment option. If federal laws prohibiting the prescription of medications composed of cannabidiol are repealed or if an exception from the general prohibition is enacted permitting the prescription of drugs composed of cannabidiol, patients should have rapid access to this treatment option. The availability of this new prescription medication is intended to augment, not to restrict or otherwise amend, other cannabinoid treatment modalities including, but not limited to, industrial hemp products and derivatives containing cannabidiol, currently available under state law.
SEC. 2.Section 26002 is added to the Business and Professions Code, to read:26002.This division shall not apply to any product containing cannabidiol that has been approved by the federal Food and Drug Administration that has either been placed on a schedule of the federal Controlled Substances Act other than Schedule I or has been exempted from one or more provisions of that act, and that is intended for prescribed use for the treatment of a medical condition.
SEC. 3.Section 11150.2 is added to the Health and Safety Code, to read:11150.2.(a)Notwithstanding any other law, if cannabidiol is excluded from Schedule I of the federal Controlled Substances Act and placed on a schedule of the act other than Schedule I, or if a product composed of cannabidiol is approved by the federal Food and Drug Administration and either placed on a schedule of the act other than Schedule I, or exempted from one or more provisions of the act, so as to permit a physician, pharmacist, or other authorized healing arts licensee acting within his or her scope of practice, to prescribe, furnish, or dispense that product, the physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses that product in accordance with federal law shall be deemed to be in compliance with state law governing those acts.
(b)For purposes of this chapter, upon the effective date of one of the changes in federal law described in subdivision (a), notwithstanding any other state law, a product composed of cannabidiol may be prescribed, furnished, dispensed, transferred, transported, possessed, or used in accordance with federal law and is authorized pursuant to state law.
(c)This section does not apply to any product containing cannabidiol that is made or derived from industrial hemp, as defined in Section 11018.5 and regulated pursuant to that section.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available, it is necessary that this act take effect immediately.
The Legislature finds and declares that both children and adults with epilepsy are in desperate need of new treatment options and that cannabidiol has shown potential as an effective treatments option. If federal laws prohibiting the prescription of medications composed of cannabidiol are repealed or if an exception from the general prohibition is enacted permitting the prescription of drugs composed of cannabidiol, patients should have rapid access to this treatment option. The availability of this new prescription medication is intended to augment, not to restrict or otherwise amend, other cannabinoid treatment modalities currently available under state law.
SEC. 2.Section 26002 is added to the Business and Professions Code, to read:26002.This division shall not apply to any product containing cannabidiol that has been approved by the federal Food and Drug Administration that has either been placed on a schedule of the federal Controlled Substances Act other than Schedule I or has been exempted from one or more provisions of that act, and that is intended for prescribed use for the treatment of a medical condition.
SEC. 3.Section 11150.2 is added to the Health and Safety Code, to read:11150.2.(a)Notwithstanding any other law, if cannabidiol is excluded from Schedule I of the federal Controlled Substances Act and placed on a schedule of the act other than Schedule I, or if a product composed of cannabidiol is approved by the federal Food and Drug Administration and either placed on a schedule of the act other than Schedule I, or exempted from one or more provisions of the act, so as to permit a physician, pharmacist, or other authorized healing arts licensee acting within his or her scope of practice, to prescribe, furnish, or dispense that product, the physician, pharmacist, or other authorized healing arts licensee who prescribes, furnishes, or dispenses that product in accordance with federal law shall be deemed to be in compliance with state law governing those acts.
(b)For purposes of this chapter, upon the effective date of one of the changes in federal law described in subdivision (a), notwithstanding any other state law, a product composed of cannabidiol may be prescribed, furnished, dispensed, transferred, transported, possessed, or used in accordance with federal law and is authorized pursuant to state law.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available, it is necessary that this act take effect immediately.
SECTION 1.Section 101.7 of the Business and Professions Code is amended to read:101.7.(a)Notwithstanding any other provision of law, boards shall meet at least three times each calendar year. Boards shall meet at least once each calendar year in northern California, once every other calendar year in rural California, and once each calendar year in southern California in order to facilitate participation by the public and its licensees.(b)The director at his or her discretion may exempt any board from the requirement in subdivision (a) upon a showing of good cause that the board is not able to meet at least three times in a calendar year.(c)The director may call for a special meeting of the board when a board is not fulfilling its duties.(d)An agency within the department that is required to provide a written notice pursuant to subdivision (a) of Section 11125 of the Government Code, may provide that notice by regular mail, email, or by both regular mail and email. An agency shall give a person who requests a notice the option of receiving the notice by regular mail, email, or by both regular mail and email. The agency shall comply with the requesters chosen form or forms of notice.(e)An agency that plans to Web cast a meeting shall include in the meeting notice required pursuant to subdivision (a) of Section 11125 of the Government Code a statement of the boards intent to Web cast the meeting. An agency may Web cast a meeting even if the agency fails to include that statement of intent in the notice.(a)Notwithstanding any other provision of law, boards shall meet at least three times each calendar year. Boards shall meet at least once each calendar year in northern California, once every other calendar year in rural northern California, and once each calendar year in southern California in order to facilitate participation by the public and its licensees.
(b)The director at his or her discretion may exempt any board from the requirement in subdivision (a) upon a showing of good cause that the board is not able to meet at least three times in a calendar year.
(c)The director may call for a special meeting of the board when a board is not fulfilling its duties.
(d)An agency within the department that is required to provide a written notice pursuant to subdivision (a) of Section 11125 of the Government Code, may provide that notice by regular mail, email, or by both regular mail and email. An agency shall give a person who requests a notice the option of receiving the notice by regular mail, email, or by both regular mail and email. The agency shall comply with the requesters chosen form or forms of notice.
(e)An agency that plans to Web cast a meeting shall include in the meeting notice required pursuant to subdivision (a) of Section 11125 of the Government Code a statement of the boards intent to Web cast the meeting. An agency may Web cast a meeting even if the agency fails to include that statement of intent in the notice.
(a)Notwithstanding any other provision of law, boards shall meet at least three times each calendar year. Boards shall meet at least once each calendar year in northern California California, once every other calendar year in rural northern California, and once each calendar year in southern California in order to facilitate participation by the public and its licensees.
(b)The director at his or her discretion may exempt any board from the requirement in subdivision (a) upon a showing of good cause that the board is not able to meet at least three times in a calendar year.
(c)The director may call for a special meeting of the board when a board is not fulfilling its duties.
(d)An agency within the department that is required to provide a written notice pursuant to subdivision (a) of Section 11125 of the Government Code, may provide that notice by regular mail, email, or by both regular mail and email. An agency shall give a person who requests a notice the option of receiving the notice by regular mail, email, or by both regular mail and email. The agency shall comply with the requesters chosen form or forms of notice.
(e)An agency that plans to Web cast a meeting shall include in the meeting notice required pursuant to subdivision (a) of Section 11125 of the Government Code a statement of the boards intent to Web cast the meeting. An agency may Web cast a meeting even if the agency fails to include that statement of intent in the notice.
SECTION 1.Section 101.6 of the Business and Professions Code is amended to read:101.6.The boards, bureaus, and commissions in the department are established for the purpose of ensuring that those private businesses and professions deemed to engage in activities that have potential impact upon the public health, safety, and welfare are adequately regulated in order to protect the people of California.To this end, they establish minimum qualifications and levels of competency and license persons desiring to engage in the occupations they regulate upon determining that such persons possess the requisite skills and qualifications necessary to provide safe and effective services to the public, or register or otherwise certify persons in order to identify practitioners and ensure performance according to set and accepted professional standards. They provide a means for redress of grievances by investigating allegations of unprofessional conduct, incompetence, fraudulent action, or unlawful activity brought to their attention by members of the public and institute disciplinary action against persons licensed or registered under the provisions of this code when such action is warranted. In addition, they conduct periodic checks of licensees, registrants, or otherwise certified persons in order to ensure compliance with the relevant sections of this code.The boards, bureaus, and commissions in the department are established for the purpose of ensuring that those private businesses and professions deemed to engage in activities which that have potential impact upon the public health, safety, and welfare are adequately regulated in order to protect the people of California.
To this end, they establish minimum qualifications and levels of competency and license persons desiring to engage in the occupations they regulate upon determining that such persons possess the requisite skills and qualifications necessary to provide safe and effective services to the public, or register or otherwise certify persons in order to identify practitioners and ensure performance according to set and accepted professional standards. They provide a means for redress of grievances by investigating allegations of unprofessional conduct, incompetence, fraudulent action, or unlawful activity brought to their attention by members of the public and institute disciplinary action against persons licensed or registered under the provisions of this code when such action is warranted. In addition, they conduct periodic checks of licensees, registrants, or otherwise certified persons in order to ensure compliance with the relevant sections of this code.
|
Date
|
Status
|
|---|---|
| Jul 9, 2018 | Chaptered by Secretary of State - Chapter 62, Statutes of 2018. |
| Jul 9, 2018 | Approved by the Governor. |
| Jun 26, 2018 | Enrolled and presented to the Governor at 3 p.m. |
| Jun 18, 2018 | Urgency clause adopted. Senate amendments concurred in. To Engrossing and Enrolling. |
| Jun 14, 2018 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after June 16 pursuant to Assembly Rule 77. |
| Jun 14, 2018 | Read third time. Urgency clause adopted. Passed. Ordered to the Assembly. |
| May 23, 2018 | Read second time. Ordered to third reading. |
| May 22, 2018 | From committee: Be ordered to second reading pursuant to Senate Rule 28.8. |
| May 15, 2018 | From committee: Do pass and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 7. Noes 0.) (May 15). Re-referred to Com. on APPR. |
| Apr 19, 2018 | Re-referred to Com. on PUB. S. |
| Apr 9, 2018 | From committee: Do pass and re-refer to Com. on RLS. (Ayes 9. Noes 0.) (April 9). Re-referred to Com. on RLS. |
| Apr 2, 2018 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E.D. |
| Apr 2, 2018 | In committee: Set, second hearing. Hearing canceled at the request of author. |
| Jan 18, 2018 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E.D. |
| Jun 19, 2017 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Jun 6, 2017 | In committee: Hearing postponed by committee. |
| May 24, 2017 | Referred to Com. on B., P. & E.D. |
| May 11, 2017 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 11, 2017 | Read third time. Passed. Ordered to the Senate. (Ayes 77. Noes 0. Page 1488.) |
| May 4, 2017 | Read second time. Ordered to Consent Calendar. |
| May 3, 2017 | From committee: Do pass. To Consent Calendar. (Ayes 16. Noes 0.) (May 3). |
| May 1, 2017 | Re-referred to Com. on APPR. |
| Apr 27, 2017 | From committee chair, with author's amendments: Amend, and re-refer to Com. on APPR. Read second time and amended. |
| Apr 19, 2017 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (April 18). Re-referred to Com. on APPR. |
| Mar 28, 2017 | Re-referred to Com. on B. & P. |
| Mar 27, 2017 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Mar 23, 2017 | Referred to Com. on B. & P. |
| Feb 16, 2017 | From printer. May be heard in committee March 18. |
| Feb 15, 2017 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 18, 2018 | AB 710 WOOD Concurrence - Urgency Added | Assembly Floor |
Passed |
|
| Jun 14, 2018 | Assembly 3rd Reading AB710 Wood By Hill Urgency Clause | Senate Floor |
Passed |
|
| May 15, 2018 | Do pass, but first be re-referred to the Committee on [Appropriations] with the recommendation: To Consent Calendar | Senate Standing Committee on Public Safety |
Passed |
|
| Apr 9, 2018 | Do pass, but first be re-referred to the Committee on [Rules] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| May 11, 2017 | AB 710 WOOD Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| May 3, 2017 | Do pass. To Consent Calendar. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 18, 2017 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 710
Author:(Wood)
As Amended Ver:April 2, 2018
2/3 vote. Urgency
ASSEMBLY: |
| (May 11, 2017) | SENATE: | 37-0 | (June 14, 2018) |
(vote not relevant)
Original Committee Reference: B. & P.
SUMMARY: Provides that if cannabidiol (CBD) is federally rescheduled or otherwise made a legally prescribable controlled substance, it shall also be legal to prescribe under state law. Specifically, this bill:
- Finds and declares that cannabidiol (a cannabinoid derived from cannabis that does not produce a psychoactive "high") has been found effective to treat epilepsy, and that changes to federal laws generally prohibiting prescriptions of cannabis products are being contemplated to allow for cannabidiol medical treatments.
- Exempts any cannabidiol product that has been approved by the federal Food and Drug Administration and federally rescheduled or otherwise made legally prescribable from the state's Medicinal and Adult-Use Cannabis Regulation and Safety Act, which provides for California's regulation of legalized cannabis.
- Authorizes health practitioners and pharmacists to prescribe and dispense cannabidiol products that have been approved by the federal Food and Drug Administration and federally rescheduled or otherwise made legally prescribable, with the exception of products derived from industrial hemp, which is otherwise regulated.
- Includes an urgency clause justified through the need to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available.
The Senate amendments deleted the contents of the bill that was previously voted on in the Assembly and inserted the provisions regarding cannabidiol.
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code (HSC) Section 11150)
- States that a prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. (HSC Section 11153)
- Enacts the Medicinal and Adult-Use Cannabis Regulation and Safety Act to provide for a comprehensive regulatory framework for the cultivation, distribution, transport, storage, manufacturing, processing, and sale of medicinal and adult-use cannabis. (Business and Professions Code (BPC) Section 26000 et al.)
FISCAL EFFECT: According to the Senate Appropriations Committee, pursuant to Senate Rule 28.8, negligible state costs.
COMMENTS:
Purpose. This bill is sponsored by the Epilepsy Foundation of Greater Los Angeles. According to the author:
Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Approximately one in 26 Americans will develop epilepsy at some point in their lifetime. There is no "one size fits all" treatment option and about one million people live with uncontrolled or intractable seizures. Uncontrolled seizures can lead to disability, injury, and even death, and many individuals living with uncontrolled seizures suffer from rare epilepsies characterized by seizures that are difficult to treat with existing treatment options. Access to new treatments is particularly important for these individuals, who live with the continual risk of serious injuries and loss of life.
The Food and Drug Administration (FDA) is currently reviewing at least one CBD derived therapy that shows promise for the treatment of rare epilepsy conditions. This potential treatment option has both "Orphan Drug Designation" and Fast Track Designation from the FDA. Given the Fast Track Designation, this potential treatment option could be available as soon as Summer 2018.
Currently, any product that contains any material, compound, mixture, or preparation, which contains any quantity of marijuana is considered a Schedule I Controlled Substance unless specifically exempted. Under current law, should a product derived from CBD, like Epidiolex, be approved and rescheduled, it would still be considered a Schedule I substance under California statute and therefore could not be prescribed by a physician unless specifically exempted. Individuals suffering from these rare forms of epilepsy and those living with uncontrolled seizures would not be able to access the medication. AB 710 will ensure Californians with uncontrolled seizures have continued access to FDA approved epilepsy treatments derived from CBD.
Background.
Regulation of Cannabis in California. In the spring of 2017, SB 94 (Budget and Fiscal Review Committee), Chapter 27, reconciled the distinct systems for the regulation, licensing, and enforcement of cannabis established under the Legislature's Medical Cannabis Regulation and Safety Act (MCRSA) and Proposition 64, the Adult Use of Marijuana Act. The single consolidated system established by the bill—known as the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA)—created a unified series of cannabis laws and deleted redundant code sections no longer necessary due to the combination of the two systems. MAUCRSA also clarified a number of components, including but not limited to licensing, local control, taxation, testing, and edibles.
As of January 1, 2018, the state has begun issuing temporary licenses (adult-use and medicinal) to cannabis businesses as the state's regulatory agencies worked toward the finalization of their regulations. While an electronic Track-and-Trace system was implemented pursuant to MAUCRSA, it is not currently being used for temporary licensees. Other licensing requirements will not be enforced until the completion of a grace period later in the year. Collectives and cooperatives previously authorized to engage in unlicensed cannabis cultivation are allowed to continue operating until January 9, 2019.
Federal Ban on Cannabis. The federal Controlled Substances Act classifies a number of drugs and chemicals into one of five schedules. Drugs falling within Schedules II through V may be prescribed only by health practitioners in possession of a Drug Enforcement Administration (DEA) registration and are ranked according to the drug's potential for abuse, with lower numbered schedules representing drugs with a higher risk of abuse or dependence. Schedule I drugs have been determined to have no currently accepted medical use and a high potential for abuse. Schedule I drugs may not be prescribed by any health practitioner in the United States. Examples of Schedule I drugs are heroin, ecstasy, and cannabis.
Cannabis's continued Schedule I status under the federal Controlled Substances Act has created a constant threat of action by the federal government, leading to apprehension among California's cannabis community. A document issued by the United States Attorney General in 2013 known as the "Cole memorandum" indicated that the existence of a strong and effective state regulatory system, and a cannabis operation's compliance with such a system, could allay the threat of federal enforcement interests. Federal prosecutors were urged under the memo to review cannabis cases on a case-by-case basis and consider whether a cannabis operation was in compliance with a strong and effective state regulatory system prior to prosecution. However, on January 4, 2018, U.S. Attorney General Jeff Sessions formally rescinded the Cole memo.
Pharmacological Applications of Cannabis. Another implication of cannabis's Schedule I status is a relative lack of scientific research regarding the risks and benefits of cannabis and products derived from cannabis. The federal government has historically restricted what institutions in receipt of federal funding may study in regards to Schedule I controlled substances. However, SB 847 ((Vasconcellos et al.) Chapter 750) of 2000 established the University of California San Diego Center for Medicinal Cannabis Research, which has produced multiple of studies regarding the medical benefits of cannabis. Proposition 64 appropriates $2 million in funding from cannabis excise tax revenue to the center to further its objectives, including studies into the efficacy and adverse effects of cannabis as a pharmacological agent.
The federal FDA, meanwhile, has stated that it "supports researchers [in states that have removed restrictions on medical cannabis] who conduct adequate and well-controlled clinical trials which may lead to the development of safe and effective marijuana products to treat medical conditions." The FDA has not yet approved any product containing or derived from botanical marijuana for any indication," meaning that the FDA "has not found any such product to be safe or effective for the treatment of any disease or condition." However, the FDA has approved drugs containing a synthetic tetrahydrocannabinol (THC) for therapeutic uses, including for the treatment of anorexia associated with weight loss in AIDS patients.
In April of 2018, an FDA advisory panel recommended approval of a drug called Epidiolex, an epilepsy medication containing ingredients derived from cannabis. The drug is currently in Phase 3 trials with the FDA. The advisory panel acknowledged the drug's potential to treat two rare forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. These syndromes are considered to be among the most difficult types of epilepsy to treat and cause frequent seizures in patients. Advocates for the epileptic community have actively championed the FDA's approval of Epidiolex, leading to a reasonable probability that it could become the first federally approved drug containing cannabinoids. This bill would ensure the drug would also be legal in California.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301 FN: 0002995
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 710
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 4/9/18
AYES: Hill, Fuller, Dodd, Galgiani, Glazer, Hernandez, Newman, Pan, Wilk
SENATE PUBLIC SAFETY COMMITTEE: 7-0, 5/15/18
AYES: Skinner, Anderson, Bradford, Jackson, Mitchell, Stone, Wiener
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: Not relevant
SOURCE: Epilepsy Foundation of Greater Los Angeles
DIGEST:
This bill amends the Medicinal and Adult-Use Cannabis Regulation and Safety Act (Act) to exclude federally sanctioned cannabidiol (CBD) products from regulation and authorizes healing arts licensees to prescribe such products, as specified.
Existing law:
- Establishes the federal Controlled Substances Act (federal Act) which regulates the manufacture, importation, possession, use, and distribution of controlled substances such as hallucinogens, narcotics, depressants, and stimulants. Categorizes drugs into five schedules based on their potential for abuse, status in international treaties, and any medical benefits they may provide. Specifies that Schedule I drugs, including marijuana, are considered the most harmful and have no medical benefitsm and Schedule 5 substances are the least restricted. (21 United States Code § 812)
- Establishes the California Uniform Controlled Substances Act (UCSA), which classifies controlled substances into five designated schedules, with the most restrictive limitations placed on controlled substances classified as Schedule I (including cannabis), and the least restrictive limitations placed on Schedule 5. (Health and Safety Code (HSC) § 11000 et seq.)
- Authorizes a physician, dentist, podiatrist, veterinarian, naturopathic doctor, a registered nurse, a certified nurse-midwife, a nurse practitioner, a physician assistant, or an optometrist to write or issue a prescription, as specified.
(HSC § 11150) - Specifies the punishment for the unauthorized selling, dispensing, distributing, furnishing, administering, giving, or offering to sell, dispense, distribute, furnish, administer, or give, or possession for sale, any synthetic CBD compound, or any synthetic CBD derivative, to any person. (HSC § 11357.5(a))
- Establishes the Act to regulate the cultivation, processing, and sale of medicinal and adult-use cannabis within the state, and permits adults 21 years of age or older to legally grow, possess, and use cannabis for non-medical purposes, as specified. (Business and Professions Code (BPC) § 26000)
- Establishes the Bureau of Marijuana Control within the Department of Consumer Affairs for the licensure and regulation of cannabis.
(BPC § 26010) - Authorizes the cultivation, testing, manufacturing, and distribution of cannabis by state and local permit only. (BPC §§ 26053, 26050, 26032)
- Declares it unlawful for a physician and surgeon who recommends cannabis to a patient for a medical purpose to accept, solicit, or offer any form of remuneration from or to a licensed medical cannabis facility, if the physician and surgeon or his or her immediate family have a financial interest in that facility. (BPC § 2525)
- Prohibits a physician and surgeon from recommending medical cannabis to a patient unless that person is the patient’s attending physician. (BPC § 2525.2)
- Declares recommending medical cannabis to a patient for a medical purpose without an appropriate prior examination and a medical indication as unprofessional conduct. (BPC § 2525.3)
This bill:
- Makes legislative findings and declarations relating to the potential benefits of CBD in treating epilepsy.
- Excludes from regulation under the Act any medicinal product containing CBD that has been approved by the federal Food and Drug Administration (FDA) that has either been placed on a schedule of the federal Act other than Schedule I, or exempted from one or more provisions of the federal Act, and is intended for prescribed use for the treatment of a medical condition.
- Declares that, upon change in federal law permitting the prescription, furnishing, or dispensing of a CBD product, a physician, pharmacist, or other authorized healing arts licensee acting within his or her scope of practice who prescribes, furnishes, or dispenses a CBD product in accordance with federal law, shall be deemed to be in compliance with state law.
- Declares that, notwithstanding any other law, the prescribing, furnishing, dispensing, transfer, transportation, possession, or use of CBD products in accordance with federal law is authorized pursuant to the UCSA upon the effective date of the change in federal law.
- Declares this bill as an urgency statute in order to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available.
- Clarifies that this bill does not apply to any product containing CBD that is made or derived from industrial hemp, as specified.
Background
CBD. According to the National Institute of Health, CBD is a compound isolated from cannabis which does not cause psychoactive activity and has pain relieving, anti-inflammatory, anti-psychotic, and tumor-inhibiting properties.
FDA drug approval process. The FDA reviews drug applications to determine whether they are safe and effective through scientific investigations, including adequate and well-controlled clinical trials.
The FDA has several programs to facilitate the approval of drugs for certain conditions. The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition which qualifies the sponsor for various development incentives, including tax credits for qualified clinical testing. “Fast track” is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
The drug Epidiolex, a CBD drug candidate with both Orphan Drug and Fast Track designation, was unanimously recommended approval by an FDA advisory panel on Thursday, April 19, 2018. According to The New York Times, FDA will vote in June whether to approve Epidiolex for the treatment of severe forms of epilepsy.
This bill is intended to facilitate the use of any FDA-approved CBD product, such as Epidiolex, by stating that federal reclassification from Schedule I or other federal action permitting the lawful prescription of a CBD drug will automatically allow the prescription and dispensing of such a drug in California. This bill also exempts such a product from regulation under the Act.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
Epilepsy Foundation of Greater Los Angeles (source)
BioCom
CalAsian Chamber of Commerce
Epilepsy Foundation of Northern California
Southern California Coalition
Vote Hemp
OPPOSITION: (Verified 5/23/18)
None received
ARGUMENTS IN SUPPORT: The Epilepsy Foundation of Greater Los Angeles writes, “Access to new therapies is particularly important for the one-third of people living with epilepsy who experience intractable or uncontrolled seizures, are living with rare epilepsies, and the many more who experience significant adverse effects from their current medication.
“Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. In the United States, 1 in 26 people will develop epilepsy in his or her lifetime. There are nearly 350,000 people with epilepsy in California. There is no ‘one size fits all’ treatment option and about 1 Million people in the United States live with uncontrolled or intractable seizures. Uncontrolled seizures can lead to disability, injury, and even death. Many of the individuals living with uncontrolled seizures suffer from rare epilepsies characterized by seizures that are difficult to treat with existing treatment options. Access to new treatments is particularly important for these individuals, who live with the continual risk of serious injuries and loss of life.”
5/24/18 14:30:41
**** END ****
SENATE COMMITTEE ON PUBLIC SAFETY
Senator Nancy Skinner, Chair
2017 - 2018 Regular
Bill No: AB 710 Hearing Date: May 15, 2018
Author: | Wood | ||
Version: | April 2, 2018 | ||
Urgency: | Yes | Fiscal: | Yes |
Consultant: | SJ | ||
Subject: Cannabidiol
HISTORY
Source: Epilepsy Foundation of Greater Los Angeles
Prior Legislation: SB 94 (Comm. on Budget and Fiscal Review), Ch. 27, Stats. of 2017
AB 845 (Wood), held in Senate Appropriations 2017
SB 643 (McGuire), Ch. 719, Stats. of 2015
AB 266 (Bonta) Ch. 689, Stats. of 2015
AB 243 (Wood) Ch. 688, Stats. of 2015
Support: Epilepsy Foundation of Northern California; Southern California Coalition;
Vote Hemp
Opposition: None known
PURPOSE
The purpose of this bill is to authorize healing arts licensees to prescribe cannabidiol (CBD) products if one of specified changes in federal law occurs, and to amend the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) to exclude federally approved products from regulation.
Existing federal law establishes the Controlled Substances Act (CSA) which regulates the manufacture, importation, possession, use, and distribution of controlled substances such as hallucinogens, narcotics, depressants, and stimulants. Categorizes drugs into five schedules based on their potential for abuse and medical utility. Specifies that Schedule I drugs, including marijuana, are considered the most harmful and have no medical benefits. (21 U.S.C. § 812.)
Existing law establishes the Uniform Controlled Substances Act (UCSA), which classifies controlled substances into five designated schedules, with the most restrictive limitations placed on Schedule I controlled substances, including cannabis, and the least restrictive limitations placed on Schedule 5 controlled substances. (Health & Saf. Code, § 11000 et seq.)
Existing law authorizes a physician, dentist, podiatrist, veterinarian, naturopathic doctor, a registered nurse, a certified nurse-midwife, a nurse practitioner, a physician assistant, or an optometrist to write or issue a prescription, as specified. (Health & Saf. Code, § 11150.)
Existing law requires a prescription for a controlled substance to be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. Indicates that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Indicates that any person who knowingly violates this provision shall be punished by imprisonment not exceeding one year, or by a fine not exceeding $20,000, or by both fine and imprisonment. (Health & Saf. Code, § 11153.)
Existing law specifies the punishment for the unauthorized selling, dispensing, distributing, furnishing, administering, giving, or offering to sell, dispense, distribute, furnish, administer, or give, or possession for sale, any synthetic CBD compound, or any synthetic CBD derivative, to any person. (Health & Saf. Code, § 11357.5, subd. (a).)
Existing law establishes the regulation of the cultivation, processing, and sale of medicinal and adult-use cannabis within the state, and permits adults 21 years of age or older to legally grow, possess, and use cannabis for non-medical purposes, as specified. (Bus. & Prof. Code, § 26000 et seq.)
Existing law establishes the Bureau of Cannabis Control (Bureau) within the Department of Consumer Affairs for the licensure and regulation of cannabis. (Bus. & Prof. Code, § 26010.)
Existing law authorizes the cultivation, testing, manufacturing, and distribution of cannabis by state and local permit only. (Bus. & Prof. Code, §§ 26032, 26050, 26053.)
Existing law prohibits a physician and surgeon from recommending medical cannabis to a patient unless that person is the patient’s attending physician. (Bus. & Prof. Code, § 2525.2.)
Existing law provides that recommending medical cannabis to a patient for a medical purpose without an appropriate prior examination and a medical indication is unprofessional conduct. (Bus. & Prof. Code, § 2525.3.)
This bill makes the following Legislative findings and declarations:
- Both children and adults with epilepsy are in need of new treatment options and that CBD has shown potential as an effective treatment option.
- If federal laws prohibiting the prescription of medications composed of CBD are repealed or if an exception from the general prohibition is enacted permitting the prescription of drugs composed of CBD, patients should have rapid access to this treatment option.
- The availability of this new prescription medication is intended to augment, not to restrict or otherwise amend, other cannabinoid treatment modalities including, but not limited to, industrial hemp products and derivatives containing CBD, currently available under state law.
This bill excludes from regulation under the MAUCRSA any medicinal product containing CBD that has been approved by the federal Food and Drug Administration (FDA) that has either been placed on a schedule of the federal CSA other than Schedule I, or has been exempted from one or more provisions of that act, and is intended for prescribed use for the treatment of a medical condition.
This bill provides that, upon change in federal law permitting the prescription, furnishing, or dispensing of a CBD product, a physician, pharmacist, or other authorized healing arts licensee acting within his or her scope of practice who prescribes, furnishes, or dispenses a CBD product in accordance with federal law, shall be deemed to be in compliance with state law.
This bill provides that, notwithstanding any other law, the prescribing, furnishing, dispensing, transfer, transportation, possession, or use of CBD products in accordance with federal law is authorized pursuant to the UCSA upon the effective date of the change in federal law.
This bill clarifies that this bill does not apply to any product containing CBD that is made or derived from industrial hemp, as specified.
This bill declares this act as an urgency statute necessary to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available.
COMMENTS
- Need for This Bill
According to the author:
Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Approximately 1 in 26 Americans will develop epilepsy at some point in their lifetime. There is no “one size fits all” treatment option and about one million people live with uncontrolled or intractable seizures. Uncontrolled seizures can lead to disability, injury, and even death, and many individuals living with uncontrolled seizures suffer from rare epilepsies characterized by seizures that are difficult to treat with existing treatment options. Access to new treatments is particularly important for these individuals, who live with the continual risk of serious injuries and loss of life.
The FDA is currently reviewing at least one CBD derived therapy that shows promise for the treatment of rare epilepsy conditions. This potential treatment option has both “Orphan Drug Designation” and Fast Track Designation from the FDA. Given the Fast Track Designation, this potential treatment option could be available as soon as Summer 2018.
Currently, any product that contains any material, compound, mixture, or preparation, which contains any quantity of marijuana is considered a Schedule I Controlled Substance unless specifically exempted. Under current law, should a product derived from CBD, like Epidiolex, be approved and rescheduled, it would still be considered a Schedule I substance under California statute and therefore could not be prescribed by a physician unless specifically exempted. Individuals suffering from these rare forms of epilepsy and those living with uncontrolled seizures would not be able to access the medication. AB 710 will ensure Californians with uncontrolled seizures have continued access to FDA approved epilepsy treatments derived from CBD.
- CBD
Cannabinoids are chemical components of cannabis that produce pharmacologic effects throughout the body, including the central nervous system and the immune system. The primary active cannabinoid in cannabis is delta-9-tetrahydrocannabinol (THC). Another active cannabinoid is CBD. According to the National Institute of Health, CBD is a compound isolated from cannabis which does not cause psychoactive activity and has pain relieving, anti-inflammatory, anti-psychotic, and tumor-inhibiting properties. Cannabinoids can be ingested, inhaled, or sprayed under the tongue. Two cannabinoids, dronabinol and nabilone, are FDA-approved drugs used for the prevention or treatment of chemotherapy-related nausea and vomiting.
There are currently over 100 clinical trials of CBD listed on the National Library of Medicine’s website. These trials are testing CBD’s utility in treating epilepsy, substance use disorders, pain, psychosis, and anxiety, among other disorders and conditions. (<https://clinicaltrials.gov/ct2/results?term=cannabidiol&Search=Clear&age_v=&gndr=&type=&rslt=> [as of May 1, 2018].)
- FDA Drug Approval Process
The FDA reviews drug applications to determine whether new drugs are safe and effective through scientific investigations, including adequate and well-controlled clinical trials. The FDA has several programs to facilitate the approval of drugs for certain conditions. The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition which qualifies the sponsor for various development incentives, including tax credits for qualified clinical testing. “Fast track” is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions.
The FDA has “not yet approved any product containing or derived from botanical marijuana for any indication,” meaning that the FDA “has not found any such product to be safe or effective for the treatment of any disease or condition.” (<https://www.fda.gov/newsevents/publichealthfocus/ucm421168.htm#notapproved> [as of May 1, 2018].) However, the FDA has approved Marinol and Syndros—both of which contain dronabinol, a synthetic THC—for therapeutic uses, including for the treatment of anorexia associated with weight loss in AIDS patients. Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, a synthetically derived cannabinoid which has a chemical structure similar to THC. (Id.)
Epidiolex is a CBD drug candidate manufactured by GW Pharmaceuticals that is currently in clinical trials with the FDA. GW Pharmaceuticals plans to market Epidiolex to treat Dravet syndrome and Lennox-Gastaut syndrome (LGS), two rare and severe forms of childhood epilepsy. On April 19, 2018, an FDA advisory committee recommended approval of Epidiolex. (<https://www.cnn.com/2018/04/19/health/fda-committee-marijuana-drug-epilepsy-bn/index.html> [as of May 1, 2018.]) The FDA’s vote on whether to approve the drug is expected by late June. (<https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-announces-acceptance-nda-filing-epidiolex%C2%AE-cannabidiol-treatment> [as of May 1, 2018].)
This bill is intended to facilitate the prescription of any FDA-approved CBD product by stating that federal reclassification or exemption from Schedule I triggers the safe prescription, furnishing, dispensing, transfer, possession, or use of a product composed of CBD in accordance with federal and state law. This bill also exempts such a product from regulation under the MAUCRSA.
- Prior Legislation
A substantially similar bill, AB 845 (Woods), was introduced last year. AB 845 passed out of this Committee but was held in the Senate Appropriations Committee.
-- END --
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Jerry Hill, Chair
2017 - 2018 Regular
Bill No: AB 710 Hearing Date: April 9, 2018
Author: | Wood | ||
Version: |
| ||
Urgency: | Fiscal: | ||
Consultant: | Sarah Huchel and Matthew Waldron | ||
Subject: Cannabidiol
SUMMARY:
Amends the Medicinal and Adult-Use Cannabis Regulation and Safety Act (Act) to exclude federally sanctioned cannabidiol (CBD) products from regulation and authorizes healing arts licensees to prescribe such products, as specified.
Existing law:
- Establishes the federal Controlled Substances Act (federal Act) which regulates the manufacture, importation, possession, use, and distribution of controlled substances such as hallucinogens, narcotics, depressants, and stimulants. Categorizes drugs into five schedules based on their potential for abuse, status in international treaties, and any medical benefits they may provide. Specifies that Schedule I drugs, including marijuana, are considered the most harmful and have no medical benefitsm and Schedule 5 substances are the least restricted. (21 United States Code § 812)
- Establishes the California Uniform Controlled Substances Act (UCSA), which classifies controlled substances into five designated schedules, with the most restrictive limitations placed on controlled substances classified as Schedule I (including cannabis), and the least restrictive limitations placed on Schedule 5. (Health and Safety Code (HSC) § 11000 et seq.)
- Authorizes a physician, dentist, podiatrist, veterinarian, naturopathic doctor, a registered nurse, a certified nurse-midwife, a nurse practitioner, a physician assistant, or an optometrist to write or issue a prescription, as specified.
(HSC § 11150) - Requires, under UCSA, a prescription for a controlled substance to be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. Indicates that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Indicates that any person who knowingly violates this provision shall be punished by imprisonment not exceeding one year, or by a fine not exceeding $20,000, or by both fine and imprisonment. (HSC § 11153)
- Specifies the punishment for the unauthorized selling, dispensing, distributing, furnishing, administering, giving, or offering to sell, dispense, distribute, furnish, administer, or give, or possession for sale, any synthetic CBD compound, or any synthetic CBD derivative, to any person. (HSC § 11357.5(a))
- Establishes the Act to regulate the cultivation, processing, and sale of medicinal and adult-use cannabis within the state, and permits adults 21 years of age or older to legally grow, possess, and use cannabis for non-medical purposes, as specified. (Business and Professions Code (BPC) § 26000)
- Establishes the Bureau of Marijuana Control (Bureau) within the Department of Consumer Affairs for the licensure and regulation of cannabis. (BPC § 26010)
- Authorizes the cultivation, testing, manufacturing, and distribution of cannabis by state and local permit only. (BPC §§ 26053, 26050, 26032)
- Declares it unlawful for a physician and surgeon who recommends cannabis to a patient for a medical purpose to accept, solicit, or offer any form of remuneration from or to a licensed medical cannabis facility, if the physician and surgeon or his or her immediate family have a financial interest in that facility. (BPC § 2525)
- Prohibits a physician and surgeon from recommending medical cannabis to a patient unless that person is the patient’s attending physician. (BPC § 2525.2)
- Declares recommending medical cannabis to a patient for a medical purpose without an appropriate prior examination and a medical indication as unprofessional conduct. (BPC § 2525.3)
This bill:
- Makes Legislative findings and declarations that both children and adults with epilepsy are in need of new treatment options and that CBD has shown potential as an effective treatment option. If federal laws prohibiting the prescription of medications composed of CBD are repealed or if an exception from the general prohibition is enacted permitting the prescription of drugs composed of CBD, patients should have rapid access to this treatment option. The availability of this new prescription medication is intended to augment, not to restrict or otherwise amend, other cannabinoid treatment modalities including, but not limited to, industrial help products and derivatives containing CBD currently available under state law.
- Excludes from regulation under the Act any medicinal product containing CBD that has been approved by the federal Food and Drug Administration (FDA) that has either been placed on a schedule of the federal Act other than Schedule I, or exempted from one or more provisions of the federal Act, and is intended for prescribed use for the treatment of a medical condition.
- Declares that, upon change in federal law permitting the prescription, furnishing, or dispensing of a CBD product, a physician, pharmacist, or other authorized healing arts licensee acting within his or her scope of practice who prescribes, furnishes, or dispenses a CBD product in accordance with federal law, shall be deemed to be in compliance with state law.
- Declares that, notwithstanding any other law, the prescribing, furnishing, dispensing, transfer, transportation, possession, or use of CBD products in accordance with federal law is authorized pursuant to the UCSA upon the effective date of the change in federal law.
- Declares this act as an urgency statute in order to ensure that patients are able to obtain access to a new treatment modality as soon as federal law makes it available.
- Clarifies that this bill does not apply to any product containing CBD that is made or derived from industrial hemp, as specified.
FISCAL EFFECT:
Unknown. This bill is keyed fiscal by the Legislative Counsel, and was previously analyzed by Assembly Appropriations when it contained unrelated language.
COMMENTS:
- Purpose. This bill is sponsored by The Epilepsy Foundation of Greater Los Angeles. According to the Author’s office, “The FDA is currently reviewing at least one CBD derived therapy that shows promise for the treatment of rare epilepsy conditions. This potential treatment option has both Orphan Drug Designation and Fast Track Designation from the FDA. Given the Fast Track Designation, this potential treatment option could be available as soon as the Summer of 2018.
“Currently, any product that contains any material, compound, mixture, or preparation which contains any quantity of marijuana is considered a Schedule I controlled substance unless specifically exempted. Under current law, should a product derived from CBD, like Epidiolex, be approved and rescheduled, it would still be considered a Schedule I substance under California statute and therefore could not be prescribed by a physician unless specifically exempted. Individuals suffering from these rare forms of epilepsy and those living with uncontrolled seizures would not be able to access the medication. AB 710 will ensure Californians with uncontrolled seizures have continued access to FDA-approved epilepsy treatments derived from CBD.”
- CBD. According to the National Institute of Health, CBD is a compound isolated from cannabis which does not cause psychoactive activity and has pain relieving, anti-inflammatory, anti-psychotic, and tumor-inhibiting properties.
There are currently 141 clinical trials of CBD listed on the federal clearinghouse for publicly and privately supported clinical, clinicaltrials.gov.
- FDA Drug Approval Process. The FDA reviews drug applications to determine whether they are safe and effective through scientific investigations, including adequate and well-controlled clinical trials.
The FDA has several programs to facilitate the approval of drugs for certain conditions. The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition which qualifies the sponsor for various development incentives, including tax credits for qualified clinical testing. “Fast track” is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
According to the FDA, it has not yet approved cannabis for any medical indication. The FDA website states “However, the FDA has approved Marinol and Syndros for therapeutic uses in the United States, including for the treatment of anorexia associated with weight loss in AIDS patients. Marinol and Syndros include the active ingredient dronabinol, a synthetic delta-9- tetrahydrocannabinol (THC) which is considered the psychoactive component of marijuana. Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure similar to THC and is synthetically derived.”
The drug Epidiolex, referenced by this bill’s sponsor, is a CBD drug candidate by GW Pharmaceuticals and is currently in Phase 3 trials with the FDA.
This bill is intended to facilitate the prescription of any FDA- approved CBD product by stating that federal reclassification from Schedule I triggers the safe prescription, furnishing, dispensing, transfer, possession, or use of a product composed of CBD in accordance with federal and state law. This bill also exempts such a product from regulation under the Act.
- Related Legislation this Session. SB 1409 (Wilk) makes several changes to existing law regarding industrial hemp, including deleting the requirement that industrial hemp seed cultivars be certified on or before Jan. 1, 2013, in order to be included on the list of approved hemp seed cultivars, removes “industrial hemp” from the UCSA as a fiber or oilseed crop, and deletes the requirement that industrial hemp be grown as a fiber or oilseed crop, or both. (Status: This bill is pending in the Senate Committee on Agriculture.)
SB 1273 (Hill) states that a person under 21 years of age who has any detectible amount of delta-9-tetrahydrocannabinol in his or her body shall be subject to the same license suspension as persons convicted of driving under the influence of alcohol, which is no less than one year for the first offense. The bill excludes persons under 21 years of age who have a valid physician’s recommendation or state medical ID card to consume medicinal cannabis. (Status: This bill is pending in the Senate Committee on Public Safety.)
SB 1127 (Hill) permits a parent or primary caregiver, upon the approval by a local school board, to come on to a school campus and administer medicinal cannabis to minors 18 years of age or younger and in possession of a valid physician’s recommendation. (Status: This bill is pending in the Senate Committee on Education.)
AB 845 (Wood) of 2017 was substantially similar to this bill, and would have authorized a physician to prescribe and a pharmacist to dispense CBD if it is reclassified at the federal level, or if a product composed of CBD is approved by the FDA and either not declared a Schedule I controlled substance, or exempted from the Act. (Status: This bill was held in the Senate Committee on Appropriations.)
- Prior Related Legislation. SB 643 (McGuire, Chapter 719, Statutes of 2015) established a regulatory framework for the cultivation, sale, and transport of medical cannabis by the Bureau of Medical Marijuana Regulation, the Department of Food and Agriculture, and other state entities. The bill also established parameters for physicians and surgeons to prescribe medical cannabis.
- Arguments in Support. The Epilepsy Foundation of Greater Los Angeles writes,
“Access to new therapies is particularly important for the one-third of people living with epilepsy who experience intractable or uncontrolled seizures, are living with rare epilepsies, and the many more who experience significant adverse effects from their current medication.
“Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. In the United States, 1 in 26 people will develop epilepsy in his or her lifetime. There are nearly 350,000 people with epilepsy in California. There is no “one size fits all” treatment option and about 1 Million people in the United States live with uncontrolled or intractable seizures. Uncontrolled seizures can lead to disability, injury, and even death. Many of the individuals living with uncontrolled seizures suffer from rare epilepsies characterized by seizures that are difficult to treat with existing treatment options. Access to new treatments is particularly important for these individuals, who live with the continual risk of serious injuries and loss of life.”
NOTE: Double referral to Senate Committee on Rules
SUPPORT AND OPPOSITION:
Support:
Epilepsy Foundation of Greater Los Angeles (Sponsor)
Epilepsy Foundation of Northern California
Opposition:
None on file as of April 3, 2018.
-- END --
Date of Hearing: May 3, 2017
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez Fletcher, Chair
ABPCA Bill Id:AB 710
Author:(Wood) – As Amended Ver:April 27, 2017
Policy Committee: | Business and Professions | Vote: | 14 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill requires a board under the jurisdiction of the Department of Consumer Affairs (DCA) to meet at least once every other year in rural California.
FISCAL EFFECT:
- Minor and absorbable costs for most boards and committees within DCA.
- Additional travel costs per rural meeting of approximately $22,000 for three boards that could not absorb costs, including Guide Dogs for the Blind, $2,450, Naturopathic Medicine Committee, $3,850, and the Board of Registered Nursing, $15,910.
COMMENTS:
- Purpose. According to the author, “Current law requires each board to meet at least once in Northern California and at least once in Southern California each calendar year. This requirement helps ensure that stakeholders from all over the state have an opportunity to be heard by the boards that are responsible to regulate and license them. Unfortunately, far too many times, board meetings do not take place in the rural parts of California. A board that meets in Santa Rosa, California would satisfy the northern California requirement, but there are still hundreds of miles north of Santa Rosa. If the board did not have any other planned meetings in northern California, a person from Crescent City, California would have to travel over 300 miles and over five hours to attend the board’s meeting in Santa Rosa. [This bill] requires boards within DCA to meet at least once every other year in rural California. This will ensure that our rural communities have a fair opportunity to have their voices heard at board meetings."
- Background. The DCA issues nearly three million licenses, certificates, and approvals to individuals and businesses in over 250 categories. Within the DCA, there are 40 regulatory entities, including 26 boards, 10 bureaus, 2 committees, 1 program, and 1 commission. These entities are semiautonomous regulatory bodies with the authority to set their own priorities and policies and take disciplinary action on their licensees.
Boards usually contain both representatives of the profession and representatives of the public. The composition of each board is outlined in statute, with members appointed by the Governor and Legislature. Individuals who serve on a board are volunteers and receive a stipend of $100 for each day spent in the discharge of official duties. Board members are also reimbursed for travel and other expenses incurred to attend board meetings. Each board’s quorum requirements to conduct official board business are set forth in statute.
Existing law requires each board to meet at a minimum of three times per year; at least once in northern California and at least once in southern California. Existing law also permits the director of DCA to exempt a board from these meeting requirements upon a showing of good cause that the board is unable to meet at least three times per year.
Board meetings are subject to the Bagley-Keene Open Meeting Act (Act) which generally requires boards to publicly notice their meetings, prepare agendas, accept public testimony, and conduct their meetings in public unless specifically authorized by the Act to meet in closed session. Agendas are required to be posted at a minimum of ten days prior to the board meeting
- Prior Legislation. SB 1047 (Senate Committee on Business, Professions and Economic Development), Chapter 354, Statutes of 2007, required all regulatory boards under the DCA to meet at least three times per calendar year, at least once in Northern California and once in Southern California. The bill also authorized the Director of DCA to exempt any regulatory board from the three-meeting requirement, upon a showing of good cause, and to call a special meeting of any regulatory board when that board is not fulfilling its duties.
Analysis Prepared by: Jennifer Swenson / APPR. / (916) 319-2081
Date of Hearing: April 18, 2017
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Rudy Salas, Chair
ABPCA Bill Id:AB 710
Author:(Wood) – As Amended Ver:March 27, 2017
SUBJECT: Department of Consumer Affairs: boards: meetings.
SUMMARY: Requires boards under the jurisdiction of the Department of Consumer Affairs (DCA) to meet at least once every other year in rural northern California.
EXISTING LAW:
- States that the boards, bureaus, and commissions under the jurisdiction of the DCA are established for the purpose of ensuring that those private businesses and professions deemed to engage in activities which have potential impact upon the public health, safety, and welfare are adequately regulated in order to protect the people of California (Business and Professions Code (BPC) Section 101.6)
- Requires boards to meet at least three times each calendar year, at least once each year in northern California and once each year in Southern California in order to facilitate participation by the public and its licensees. (BPC Section 101.7(a))
- Authorizes the Director of the DCA to exempt any board from the requirement set forth in number 2) upon a showing of good cause that the board is not able to meet at least three times in a calendar year. (BPC Section 101.7(b))
- Authorizes the Director of the DCA to call for a special meeting of a board when a board is not fulfilling its duties. (BPC Section 101.7(c))
- Requires an agency that plans to webcast a meeting to include in the required meeting notice a statement of the board's intent to webcast the meeting, but does not prohibit the board from webcasting a meeting if the board fails to include the statement. (BPC Section 101.7(e))
- States that each member of a board, commission, or committee is required to receive a per diem of one hundred dollars ($100) for each day actually spent in the discharge of official duties and is to be reimbursed for traveling and other expenses necessarily incurred in the performance of official duties. (BPC Section 103)
THIS BILL:
- Requires boards under the jurisdiction of the DCA to meet at least once every other calendar year in rural northern California.
FISCAL EFFECT: Unknown. This bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author, "the California [DCA] currently oversees over forty boards within its jurisdictions. These boards are in charge of the professional licensure of medical professionals, contractors, engineers, and many other professions. Given the wide range of issues covered by each board, current law requires each board to meet at least once in Northern California and at least once in Southern California each calendar year. This meeting requirement helps ensure that stakeholders from all over the state have an opportunity to be heard by the boards that are responsible to regulate and license them. Unfortunately, far too many times, board meetings do not take place in the rural parts of northern California. A board that meets in Santa Rosa, California would satisfy the northern California requirement, but there are still hundreds of miles north of Santa Rosa. If the board did not have any other planned meetings in northern California, a person from Crescent City, California would have to travel over 300 miles and over five hours to attend the board’s meeting in Santa Rosa. [This bill] requires boards within DCA to meet at least once every other year in rural northern California. This will ensure that our rural communities have a fair opportunity to have their voices heard at board meetings."
Background. The DCA is one of eight agencies operating under the direction of the Business, Consumer Services and Housing Agency. The DCA issues almost 3 million licenses, certificates, and approvals to individuals and businesses in over 250 categories. DCA entities are semiautonomous regulatory bodies with the authority to set their own priorities and policies and take disciplinary action on their licensees. Board members are representatives of the public and of the profession a particular board oversees. The composition of each board is outlined in statute, with members appointed by the Governor and Legislature. Within the DCA are 40 entities, including 26 boards, 10 bureaus, 2committees, 1program, and 1 commission.
Board Composition and Meeting Requirements. Boards are semiautonomous entities with the authority to set their own priorities and policies and take disciplinary action on their licensees. Members of a board are usually split between representatives of the profession and representatives of the public. Board members are appointed by the Governor, the Senate Rules Committee, or the Speaker of the Assembly. The number of board members, who they represent, and who appoints them is set in state law. Membership on a DCA board is not a salaried position and those individuals who voluntarily serve on a board receive a small stipend of one hundred dollars ($100) for each day actually spent in the discharge of official duties, board members are also reimbursed for traveling and other expenses incurred to attend board meetings as specified in the BPC. Both public and professional board members are often employed in ventures outside of the board in which they sit on; professional members may have practices or businesses which are completely separate from their role as a board member. Attendance and participation at a board meeting can require board members to take time away from their current employment or family responsibilities to participate in the process. Each boards quorum requirements to conduct official board business, including taking office votes are set forth in statute.
Under current law, each board is required to meet at a minimum of three times per year; at least once in northern California and at least once in southern California. Current law also permits the director of the DCA to exempt a board from these meeting requirements upon a showing of good cause that the board is unable to meet at least three times per year. This bill would require boards to meet at least once every other year in rural northern California.
Bagley Keene Open Meeting Act. Board meetings are subject to the Bagley-Keene Open Meeting Act (Act) which generally requires boards to publicly notice their meetings, prepare agendas, accept public testimony, and conduct their meetings in public unless specifically authorized by the Act to meet in closed session. Agendas are required to be posted at a minimum of ten days prior to the board meeting there are limitations on topics addressed at a board meeting which are not noticed on the agenda. This bill would not alter boards' current requirements to comply with the provisions of the Act.
Prior Related Legislation. SB 1243 (Lieu) Chapter 395, Statutes of 2014, increased the transparency of information distributed by the DCA; requiring the DCA, the Attorney General, and the Office of Administrative Hearings to submit specified reports to the Legislature annually; enhancing unlicensed advertising enforcement; and, establishing a board member mentor program, among other things; extends until January 1, 2017 the provisions establishing the Veterinary Medical Board and the term of the executive officer; extends the Certified Common Interest Development Manager program and the Tax Preparer program until January 1, 2019.
SB 1047 (Senate Committee on Business, Professions and Economic Development), Chapter 354, Statutes of 2007, required all regulatory boards under the DCA to meet at least three times per calendar year, at least once in Northern California and once in Southern California, and authorizes the Director of DCA to exempt any regulatory board from the three-meeting requirement, upon a showing of good cause and to call a special meeting of any regulatory board when that regulatory board is not fulfilling its duties. Makes several non-controversial, minor or technical changes to statutes administered by various bureaus and boards under DCA.
IMPLEMENTATION ISSUES:
Public and stakeholder participation in board meetings are vital components of the deliberation process for boards in exercising their licensing, education and enforcement responsibilities as demonstrated by the current mandate for boards to meet in northern and southern California annually and the encouragement for boards to webcast meetings as often as possible. However, given travel, personnel, and budget constraints, the Committee may wish to note the implementation issues below:
- Rural Northern California: As currently drafted, it is unclear what defines "rural" northern California. In addition, it is unclear why requiring meetings in rural locations of California would be limited to only those in Northern California.
- Accessibility: Board members reside throughout California and are required to travel from their home city to attend board meetings which typically occur during normal business hours Monday through Friday. Travel opportunities to rural northern California could prove to be challenging for some board members which could prohibit their participation at a meeting. If the travel is too cumbersome, or requires too much time away from their current employment or family commitments, board participation could be reduced at those meetings, which could limit a board's ability to achieve a quorum.
- Costs: Boards are special fund entities and receive no General Fund monies, relying solely on fees collected from licensed persons (real estate agents, physicians, architects, accountants, etc.). Board meetings held in locations outside of Sacramento (at the DCA or other state buildings) increase board costs in the form of staff travel expenses and facility costs. Board member travel expenses, staff travel expenses, and facility rental fees are all paid for through the collection of various licensee fees. The cost to travel to rural northern California could increase (given limited travel options) board costs, thereby potentially increasing licensee fees.
- Teleconference: While teleconference opportunities may be restricted by provisions of the Act, providing access at a teleconference site in rural northern California could be helpful in enhancing public participation in rural communities.
REGISTERED SUPPORT:
None on file.
REGISTERED OPPOSITION:
None on file.
Analysis Prepared by: Elissa Silva / B. & P. / 916-319-3301
Discussed in Hearing
Assembly Floor
Senate Floor
Assembly Standing Committee on Business and Professions
Bill Author
Bill Co-Author(s):